Boryung advances health through two pillars. In pharmaceuticals, the company leads chronic disease care with the Kanarb family—its proprietary original drug—and is positioned as a global specialist in cytotoxic anti-cancer drugs. These products are produced at the EU-GMP-certified Yesan Smart Factory, which also provides world-class CDMO services and ensures the stable global supply of essential treatments. In space-based healthcare, Boryung pioneers research infrastructure and opportunities to support human survival in extreme environments. By actively collaborating with global partners to secure independent research space, the company expands opportunities for R&D and extends its mission to address health challenges both on Earth and beyond.
| Website | http://www.boryung.co.kr |
| Revenue | $640.4 million |
| Employees | 126 (61 on RocketReach) |
| Founded | 1963 |
| Phone | +1 212-947-8880 |
| Industry | Investment Management |
| Keywords | Healthcare Investment, Pharmaceutical, Human Health, Biotechnology, Life Sciences, Drug Development, Medical Research, Therapeutics, Innovative Medicines, Clinical Trials, Biologics, Health Solutions, Health Technology, Generic Drugs, Healthcare Services, Specialty Pharma, Medical Devices |
Looking for a particular Boryung employee's phone or email?
The Boryung annual revenue was $640.4 million in 2026.
Sue Kim is the CEO of Boryung.
61 people are employed at Boryung.